Intermune's orphan Esbriet escapes reference pricing in Germany
This article was originally published in Scrip
Intermune's idiopathic pulmonary fibrosis treatment Esbriet (pirfenidone) offers patients "unquantifiable" added therapeutic benefit that will later be defined in light of clinical practice, according to Germany's federal joint committee, the G-BA. The decision trumps an earlier benefit assessment declaring that the orphan drug offered no extra benefit and therefore spares it from reference pricing.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.